A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma Meeting Abstract


Authors: Slingluff, C.; Zarour, H.; Postow, M.; Friedlander, P.; Devoe, C.; Mauldin, I.; Smith, K.; Macri, M.
Abstract Title: A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma
Meeting Title: 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019)
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 7
Issue: Suppl. 1
Meeting Dates: 2019 Nov 6-10
Meeting Location: National Harbor, MD
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2019-11-01
Start Page: 282
Language: English
ACCESSION: WOS:000496473200787
PROVIDER: wos
PMCID: PMC6833189
PUBMED: 31694725
DOI: 10.1186/s40425-019-0763-1
Notes: Meeting Abstract: P366 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    361 Postow